Tags

Type your tag names separated by a space and hit enter

New drugs for the treatment of schizophrenic patients.
Acta Psychiatr Scand Suppl 1995; 388:24-30AP

Abstract

Conventional neuroleptics are widely accepted as being effective against the positive symptoms of schizophrenia, but do not benefit all patients. Furthermore, they are relatively ineffective against negative symptoms and cognitive disorders, and most have unpleasant side effect profiles. New strategies for treating schizophrenia include the development of dopamine antagonists with high selectivity for different subtypes of dopamine receptors, dopamine partial agonists, antagonists at different serotonin (5-hydroxytryptamine; 5-HT) receptor subtypes, drugs with mixed pharmacological profiles and drugs which modify transmission via amino acids or peptides in the brain. The prospect is that some of these strategies will lead to the introduction of new drugs and that some of these will become the standards against which future drugs will be compared. The search for new drugs and their use in clinical practice will also lead to developments in our knowledge and understanding of schizophrenia.

Authors+Show Affiliations

Department of Biological Psychiatry, University of Innsbruck Medical School, Austria.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

7604735

Citation

Fleischhacker, W W.. "New Drugs for the Treatment of Schizophrenic Patients." Acta Psychiatrica Scandinavica. Supplementum, vol. 388, 1995, pp. 24-30.
Fleischhacker WW. New drugs for the treatment of schizophrenic patients. Acta Psychiatr Scand Suppl. 1995;388:24-30.
Fleischhacker, W. W. (1995). New drugs for the treatment of schizophrenic patients. Acta Psychiatrica Scandinavica. Supplementum, 388, pp. 24-30.
Fleischhacker WW. New Drugs for the Treatment of Schizophrenic Patients. Acta Psychiatr Scand Suppl. 1995;388:24-30. PubMed PMID: 7604735.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - New drugs for the treatment of schizophrenic patients. A1 - Fleischhacker,W W, PY - 1995/1/1/pubmed PY - 1995/1/1/medline PY - 1995/1/1/entrez SP - 24 EP - 30 JF - Acta psychiatrica Scandinavica. Supplementum JO - Acta Psychiatr Scand Suppl VL - 388 N2 - Conventional neuroleptics are widely accepted as being effective against the positive symptoms of schizophrenia, but do not benefit all patients. Furthermore, they are relatively ineffective against negative symptoms and cognitive disorders, and most have unpleasant side effect profiles. New strategies for treating schizophrenia include the development of dopamine antagonists with high selectivity for different subtypes of dopamine receptors, dopamine partial agonists, antagonists at different serotonin (5-hydroxytryptamine; 5-HT) receptor subtypes, drugs with mixed pharmacological profiles and drugs which modify transmission via amino acids or peptides in the brain. The prospect is that some of these strategies will lead to the introduction of new drugs and that some of these will become the standards against which future drugs will be compared. The search for new drugs and their use in clinical practice will also lead to developments in our knowledge and understanding of schizophrenia. SN - 0065-1591 UR - https://www.unboundmedicine.com/medline/citation/7604735/New_drugs_for_the_treatment_of_schizophrenic_patients_ L2 - https://medlineplus.gov/schizophrenia.html DB - PRIME DP - Unbound Medicine ER -